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Abstract: Cancer immunotherapy is becoming a routine treatment modality in the oncology clinic,
in spite of the fact that it is a relatively nascent field. The challenge in developing effective
immunotherapeutics is the identification of target molecules that promote anti-tumor efficacy across
the patient population while sparing healthy tissue from damaging autoimmunity. The intestinally
restricted receptor guanylyl cyclase C (GUCY2C) is a target that has been investigated for the
treatment of colorectal cancer and numerous animal, and clinical studies have demonstrated both
efficacy and safety. Here, we describe the current state of GUCY2C-directed cancer immunotherapy
and the future directions of this work.
Keywords: colorectal cancer; immunotherapy; vaccine; adenovirus; checkpoint inhibitor;
immunotoxin; CAR-T cell
1. Introduction
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States,
with the 5-year survival prognosis for patients with Stage IV disease being only 11% [1]. Thus,
there is an unmet clinical need for novel therapeutics that can better manage, and ameliorate, the
substantive burden of late stage disease. In less than a decade, immunotherapy, the practice of
employing pharmacological intervention to redirect a patient’s immune system to unleash anti-tumor
effector functions, is becoming a primary treatment modality in the oncology clinic. Of most recent
success has been monoclonal antibody therapy directed against the T-cell inhibitory signaling molecules
cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), collectively
referred to as checkpoint inhibitors. These two drug targets have been explored in myriad solid tumors,
and the United States Food and Drug Administration (FDA) has recently granted fast track approval
for the use of the PD-1 inhibitor nivolumab (Opdivo®) for colorectal cancer patients with mismatch
repair deficient (dMMR) and microsatellite instability positive (MSI+) disease (CheckMate-142 Trial,
NCT02060188) [2]. It should be noted, however, that this therapy is effective in only a subset of MSI+
patients, with a 31% overall response rate across all enrollees (n = 74). With MSI+ disease accounting
for approximately 15% of sporadic cases, the vast majority of CRC patients, including MSI+ CRC
patients unresponsive to nivolumab, still require effective and safe therapeutic options [3].
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A major obstacle in cancer immunotherapy has been achieving the optimal balance between
specific targeting of tumor-associated antigens (TAA) and broad applicability to the patient population.
While checkpoint inhibition has been used in the treatment of melanoma, metastatic renal cell
carcinoma, non-small cell lung cancer, and now MSI+ CRC with significant anti-cancer efficacy,
the manipulation of such a broad immune regulatory pathway is not without risk. Adverse events
arising from the use of checkpoint inhibitors can cause severe autoimmunity across all organ systems,
with some cases leading to death [4]. As checkpoint inhibition continues to be used and improved with
the development of new checkpoint targets, clinicians are becoming more adept at managing toxicities;
however, it is clear that refinement of targeted therapies is required to improve outcomes. The intestinal
epithelial, transmembrane cyclase, guanylyl cyclase C (GUCY2C), is an ideal immunotherapeutic
target, because it occupies an endogenous, compartmentalized luminal niche protected from systemic
autoimmune adverse events, whereas its depolarized expression on metastatic colorectal cancer can be
targeted therapeutically.
2. Guanylyl Cyclase C
Differential expression of target TAAs has been the solution most exploited for safe and
effective immunotherapeutic targeting. The cancer-testis antigens (CTAs), including the family
of melanoma-associated antigens (MAGE) and NY-ESO-1, have routinely been used as targets
for immunotherapies in multiple cancers due to their ectopic expression in cancer, with limited
expression outside testes, which contributes to their immunogenicity and safety profile [5]. Likewise,
carcinoembryonic antigen (CEA) has also been used as a target in colorectal cancer; however,
the administration of T cells expressing a CEA-specific T cell receptor (TCR) to patients induced
severe colitis targeting intestinal CEA, thus limiting its potential [6]. While ectopic antigens aim to
exploit temporal differences in expression, cancer mucosa antigens (CMAs) focus on the unique spatial,
and environmental, differences experienced by mucosal tissues, where immune function is highly
specialized to balance the myriad commensal, food, and environmental antigens encountered regularly
with protection from truly dangerous pathogens [7].
This compartmentalization of mucosal immunity supports the therapeutic rationale for
targeting GUCY2C [8]. Expressed throughout the lifetime of mammalian organisms, GUCY2C is
a transmembrane receptor localized to the apical brush border of the intestinal epithelium, which binds
the endogenous ligands guanylin and uroguanylin, catalyzing the conversion of GTP to cGMP, and is
required to maintain intestinal homeostasis. GUCY2C is also bound and activated by a heat-stable toxin
(ST) produced by enterotoxic Escherichia coli, resulting in traveler’s diarrhea [9]. GUCY2C mRNA and
protein have also been identified in the salivary gland and hypothalamus, although function is not yet
fully understood in these tissues. Importantly, GUCY2C is expressed in greater than 80% of colorectal
tumors, with both protein and mRNA expression identified in the majority of primary and metastatic
lesions regardless of disease stage or tumor grade [10–12]. Moreover, GUCY2C is over-expressed
in colorectal tumors, with the apical restriction observed in epithelial cells being lost in malignant
cells. This depolarized over-expression, coupled with the immune compartmentalization of the
gastrointestinal tract, allows for targeting metastatic tumors enriched in GUCY2C, while the intestine
is preserved from adverse autoimmunity [13–16]. In addition, GUCY2C is expressed in approximately
60% of pancreatic, gastric, and esophageal cancers [17–19], suggesting that GUCY2C could be targeted
in those diseases as well. To date, GUCY2C biology has been exploited in experimental cancer
immunotherapy using vaccines, immunotoxins, and CAR-T cells (Figure 1).
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Figure 1. Three Primary Modalities for GUCY2C-directed Cancer Immunotherapy. 
Immunotherapeutic targeting of GUCY2C encompasses cancer vaccines, immunotoxins, and CAR-T 
cell therapy, which cover all stages of disease. The primary therapeutic purpose of the vaccine is to 
provide systemic surveillance against colorectal cancer micrometastases. Immune responses 
generated by the vaccine are not robust enough to deal with bulky tumor masses. Rather, it primes 
the immune system to produce GUCY2C-directed CD8+ T cell and B cell responses that eliminate 
micrometastatic disease following standard therapies. GUCY2C-directed CAR-T cells are designed to 
be highly effective tumor cell killers and the delivery of very large quantities of these cells makes this 
therapy ideal for bulky disease. However, this autologous therapy is not without risks or high cost 
and should be reserved for patients with late stage disease unresponsive or refractory to standard 
therapies. GUCY2C antibody drug conjugates (ADC) are a suitable therapeutic intervention for Stages 
II, III, and possibly IV, where the tumor has spread and chemotherapeutic standard of care has 
resulted in an immunocompromised patient where vaccine intervention would be unsuccessful. 
3. Vaccines 
Once GUCY2C was identified as a target antigen, animal studies were conducted to determine 
if it could be an effective target and whether autoimmunity would be a limiting factor to the success 
of this target [20]. Adenovirus, rabies virus, and vaccinia virus vaccines were designed to include the 
first 430 amino acids of GUCY2C, which encodes its extracellular domain (GUCY2CECD) [20]. BALB/c 
mice received prophylactic vaccination at 28 day intervals, either receiving a single dose of the 
adenovirus vaccine, adenovirus plus vaccinia virus, or adenovirus, rabies virus and vaccinia virus, 
with this heterologous prime-boost strategy being chosen to limit anti-vector immunity when 
boosting. The CT26 mouse colon carcinoma cell line expressing GUCY2C was implanted 
subcutaneously and tumor growth kinetics were monitored for 25 days. The adeno + rabies + vaccinia 
virus vaccination strategy reduced tumor growth and improved survival. In addition, metastatic 
models including both the liver and lungs were evaluated. In both cases, the tumor burden 
experienced by animals receiving the GUCY2C vaccine was reduced compared to controls. With 
vaccine efficacy established in these animal models, concomitant autoimmunity targeting GUCY2C-
expressing tissues was examined. Systemic effects of vaccination were determined through 
measurement of serum chemistries [20]. Creatinine, sodium, triglycerides, and chloride were outside 
the normal range for both animals receiving either control vaccine or the GUCY2C vaccine, 
suggesting either a vector- or a strain-specific, but not GUCY2C-specific, effect. Histopathological 
analyses were conducted for the entire length of the intestine with no evidence of immune cell 
Figure 1. Three Primary Modalities for GUCY2C-directed Cancer Immunotherapy. Immunotherapeutic
targeting of GUCY2C encompasses cancer vaccines, immunotoxins, and CAR-T cell therapy, which
cover all stages of disease. The primary therapeutic purpose of the vaccine is to provide systemic
surveillance against colorectal cancer micrometastases. Immune responses generated by the vaccine
are not robust enough to deal with bulky tumor masses. Rather, it primes the immune system to
produce GUCY2C-directed CD8+ T cell and B cell responses that eliminate micrometastatic disease
following standard therapies. GUCY2C-directed CAR-T cells are designed to be highly effective tumor
cell killers and the delivery of very large quantities of these cells makes this therapy ideal for bulky
disease. However, this autologous therapy is not without risks or high cost and should be reserved for
patients with late stage disease unresponsive or refractory to standard therapies. GUCY2C antibody
drug conjugates (ADC) are a suitable therapeutic intervention for Stages II, III, and possibly IV, where
the tumor has spread and chemotherapeutic standard of care has resulted in an immunocompromised
patient where vaccine intervention would be unsuccessful.
3. Vaccines
Once GUCY2C was identified as a target antigen, animal studies were conducted to determine if
it could be an effective target and whether autoimmunity would be a limiting factor to the success
of this target [20]. Adenovirus, rabies virus, and vaccinia virus vaccines were designed to include
the first 430 amino acids of GUCY2C, which encodes its extracellular domain (GUCY2CECD) [20].
BALB/c mice received prophylactic vaccination at 28 days intervals, either receiving a single dose of
the adenovirus vaccine, adenovirus plus vaccinia virus, or adenovirus, rabies virus and vaccinia virus,
with this heterologous prime-boost strategy being chosen to limit anti-vector immunity when boosting.
The CT26 mouse colon carcinoma cell line expressing GUCY2C was implanted subcutaneously and
tumor growth kinetics were monitored for 25 days. The adeno + rabies + vaccinia virus vaccination
strategy reduced tumor growth and improved survival. In addition, metastatic models including
both the liver and lungs were evaluated. In both cases, the tumor burden experienced by animals
receiving the GUCY2C vaccine was reduced compared to controls. With vaccine efficacy established in
these animal models, concomitant autoimmunity targeting GUCY2C-expressing tissues was examined.
Systemic effects of vaccination were determined through measurement of serum chemistries [20].
Creatinine, sodium, triglycerides, and chloride were outside the normal range for both animals
receiving either control vaccine or the GUCY2C vaccine, suggesting either a vector- or a strain-specific,
but not GUCY2C-specific, effect. Histopathological analyses were conducted for the entire length of the
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intestine with no evidence of immune cell infiltration or tissue pathology [20]. This work established
proof-of-concept for GUCY2C as a safe and effective cancer vaccine target.
The interplay between anti-tumor efficacy and autoimmunity was further examined in animal
models of inflammatory bowel disease [21]. After vaccination with GUCY2C-expressing adenovirus
(Ad5-GUCY2C), colitis was induced with dextran sodium sulfate (DSS), to investigate if intestinal
dysfunction due to inflammatory bowel disease is exacerbated by GUCY2C-specific immunization.
There was no difference in body weight or histopathological score between GUCY2C-vaccinated and
control-vaccinated animals. Furthermore, GUCY2C vaccination did not increase tumorigenesis in a
model of inflammation-associated colorectal cancer. This work demonstrates the potential for safe
application of GUCY2C vaccines in a therapeutic setting where CRC patients are presenting with
intestinal lesions and possibly intestinal dysfunction.
To improve anti-tumor efficacy in a therapeutic model, adjuvanation of the GUCY2C vaccine
with the cytokines GM-CSF or IL-2 was explored [22]. A lung metastases model was established
with GUCY2C-expressing CT26 cells, with animals receiving the first vaccination 3 days after tumor
implantation, followed by a boost at Day 10. During both vaccinations, GM-CSF or IL-2-expressing
plasmid DNAs were administered. There was a significant reduction in the number of lung nodules
when animals were sacrificed at Day 15 between animals receiving GUCY2C vaccine and cytokine
adjuvanation and those receiving control vaccine and cytokine adjuvanation. The number of lung
nodules was no different between control and GUCY2C-vaccinated mice not receiving cytokine
adjuvanation, suggesting that the maximal vaccine efficacy in clinical models may be aided by
the addition of cytokine therapy. In fact, in both animal models and clinical trials investigating
cell-based vaccine therapies for colorectal cancer targeting other tumor antigens, the addition of
GM-CSF improved anti-tumor efficacy [23–25].
In the context of GUCY2C vaccination, cytokine adjuvanation revealed that the maximal
therapeutic efficacy of the vaccine had not been achieved by single agent administration. Rather
than empirically determining an optimal adjuvant cocktail, the mechanistic determinants impacting
immune responses were explored. Investigators observed that anti-cancer efficacy without concomitant
autoimmunity was due to lineage-specific induction of CD8+ T-cell responses to GUCY2C, without
CD4+ helper T-cell or antibody responses [21]. This finding suggested that, while vaccination was
effective, the opportunity existed to dramatically improve vaccine efficacy if a CD4+ helper T-cell
response could be induced. The development of GUCY2C-deficient (Gucy2c−/−) mice permitted
the study of self-tolerance mechanisms, which produce selective CD8+ T-cell, but not CD4+ T- or
B-cell, responses to GUCY2C. As expected, Gucy2c−/− mice immunized with Ad5-GUCY2C, produced
robust CD8+ T-cell, CD4+ T-cell, and B-cell responses, whereas the wild type counterparts did not [26].
Although the mechanisms underlying this selective tolerance remain incompletely defined, it offered
a potential strategy to improve vaccine efficacy by engineering a CD4+ helper T-cell epitope into
the vaccine [26]. The epitope selected was the influenza HA Site 1 epitope, or S1, producing the
Ad5-GUCY2C-S1 vaccine [26]. Vaccination of wild-type animals with the Ad5-GUCY2C-S1 vaccine
produced GUCY2C-specific antibodies and increased the GUCY2C-specific CD8+ T-cell response
magnitude [26]. While a GUCY2C-specific CD4+ T-cell response was not induced, the S1-specific CD4+
T-cell response was sufficient to provide the help necessary for both B and CD8+ T cells to improve
the GUCY2C response. This improved immune response conferred a substantial improvement in
protection against colorectal cancer metastases in lungs, increasing survival 750% compared to the
conventional GUCY2C vaccine [26]. Perhaps more importantly to vaccine efficacy than the primary
immune response is the ability to generate long-lasting memory responses. The lack of CD4+ T-cell
help from the conventional vaccine negates the production of GUCY2C-specific CD8+ T cell memory
responses; however, including the S1 epitope produced memory CD8+ T-cell responses, as evidenced
by a challenge experiment where Ad5-GUCY2C-S1 vaccinated animals demonstrated a significant
survival benefit relative to conventional vaccine recipients following establishment of metastases
Toxins 2017, 9, 282 5 of 9
8–11 weeks after vaccination [26]. Thus, it was determined that the inclusion of a helper epitope was
critical to the clinical success of the GUCY2C vaccine.
As evidenced in earlier work, vaccine efficacy was increased with a prime-boost, rather than prime
alone, strategy. However, to overcome immunity targeting viral vectors, a heterologous prime-boost
strategy would need to be developed. In the earliest studies, rabies virus and vaccinia virus were
used with adenovirus; however, safety concerns with these viral vectors limit their clinical potential.
One approach being explored is a DNA vaccine, that would negate the technical challenges posed
by vector immunity, and could be used in a heterologous prime-boost strategy with the adenovirus
vaccine. Interestingly, a DNA+Ad5 heterologous prime boost strategy safely produced CD8+ T cells
with substantially higher functional avidity and anti-tumor efficacy than either vaccine alone [27].
With the demonstration of both prophylactic and therapeutic efficacy of GUCY2C vaccines, and
no observable autoimmunity, the Ad5-GUCY2C-S1 vaccine was developed for clinical use, replacing
the CD4+ helper T-cell epitope with a universal human CD4+ T-cell epitope, known as PADRE [28].
PADRE is a pan DR epitope that binds multiple human HLA DR haplotypes [29]. Starting in 2013,
10 subjects were enrolled in a Phase I clinical trial to determine the safety and immunogenicity of this
Ad5-GUCY2C-PADRE vaccine [30]. The study population included patients diagnosed with Stage
I or II colorectal cancer and who underwent surgical resection without chemotherapy. The median
age was 65 (49–76) with 50% male subjects. Subjects were administered 1011 viral particles (vp) of
Ad5-GUCY2C-PADRE intramuscularly and then followed for safety and immunomonitoring blood
collection at 30, 90, and 180 days following immunization. Adverse events (AEs) were reported by all
subjects; however, all AEs were Grade 1 with complaints including expected injection site tenderness
and flu-like symptoms. No Grade 3/4 AEs or serious adverse events were observed. Importantly, 4 out
of the 10 (40%) subjects produced a GUCY2C-specific CD8+ T-cell response. Future Phase II studies
may improve responses through repeated Ad5-GUCY2C-PADRE administrations and/or increased
vaccine dosing. Further, Ad5-GUCY2C-PADRE may be examined in patients with gastric, esophageal,
and pancreatic cancer, which often ectopically express GUCY2C.
4. Immunotoxins and Antibody-Drug Conjugates
While vaccines are designed to activate a patient’s immune system to produce an anti-tumor effect,
immunotoxins use TAA-targeted antibodies to deliver a toxic payload to TAA-expressing cancer cells.
In that context, both mouse and human-specific GUCY2C monoclonal antibodies were developed,
and employed as the basis for GUCY2C-targeted immunotoxins. Importantly, these antibodies target
the extracellular domain of GUCY2C, but do not bind its ligand-binding site, producing no effect
on GUCY2C activation. To produce an effective immunotoxin, the antibody must be internalized to
deliver its toxic payload to intracellular compartments. Importantly, upon binding, GUCY2C-specific
antibodies are internalized as a receptor-antibody complex via clathrin-mediated endocytosis to
endo/lysosomal compartments [31]. The increasing acidification of the endosomal compartment
allows for the delivery of a toxic payload conjugated to antibodies via a cleavable bond, disassociating
the toxin from the antibody, leading to cell killing through interference of vital cellular processes.
For these studies, the ricin A chain toxin was conjugated to a GUCY2C antibody through a cleavable
linker [31]. To show therapeutic efficacy, colorectal cancer metastases were established with mouse
GUCY2C-expressing CT26 cells and animals were treated with 6 doses every other day beginning
two days after tumor challenge. The tumor burden in GUCY2C immunotoxin-treated mice was lower
than controls, leading to an increase in survival. Normal tissues evaluated for histopathological
signs of damage showed no clinically significant toxicity. These findings have also been translated
to a recent Phase I clinical trial examining the GUCY2C-targeted antibody-drug conjugate TAK-264
(MLN0264) in patients with advanced gastrointestinal cancer, producing preliminary evidence of
anti-tumor efficacy in some patients, with manageable toxicity [32]. One limitation of immunotoxin or
antibody-drug conjugate therapeutics is the development of humoral immune responses targeting
the therapy, especially when employing proteinaceous toxins. Indeed, in a clinical trial examining the
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immunogenicity of a vaccine for ricin A chain, the investigators found a dose-dependent correlation
between the vaccine dose and the number of subjects generating neutralizing antibodies (NAbs) [33].
This suggests that identifying less immunogenic toxic payloads or creating multiple toxic conjugates
that can be administered sequentially to negate humoral responses to prior treatment may be
advantageous. In the context of GUCY2C immunotoxin administration, the impact of NAbs on
therapeutic efficacy has not been explored.
5. Chimeric Antigen Receptor T Cells
Many immunotherapies leverage the cytotoxic effector function of CD8+ T cells to actively kill
unwanted tumor cells. T-cell receptors (TCRs) recognize epitopes through the major histocompatibility
complex (MHC), which after the T and B cell receptors is the most genetically diverse locus in
humans. These TCRs provide the exquisite sensitivity and specificity characteristic of adaptive immune
responses. However, effective T-cell therapies are restricted by patient HLA haplotypes, which can be
both time-consuming and costly when identifying patient-specific anti-tumor TCRs and their cognate
peptide-MHCs. Chimeric antigen receptor (CAR)-T cells circumvent HLA-restriction by combining the
endogenous, native protein binding capacity of antibodies with the intracellular signaling domains of
TCRs [34,35]. This ability to directly bind the target, rather than a processed peptide epitope, provides
flexibility in terms of target, specificity, and broad applicability in the clinic. Using the same antibodies
previously described for use with immunotoxins, CAR-T cells were designed by fusing the antibody
variable domains into a single fragment (scFv) and linking this to the T-cell activation domains of
CD28, 4-1BB, and CD3ζ [36]. This construct was placed in a retroviral vector, which was used to
transduce mouse CD8+ T cells, making them genetically modified CAR-T cells [36]. Direct binding to
GUCY2C by the CAR molecules resulted in T-cell activation and cytokine (IFNγ, TNFα, and MIP-1α)
production. Polyfunctional cytokine production (the ability of a single cell to produce more than one
cytokine) was observed in over 50% of the CAR-T cell population. In vitro cytotoxicity was measured
using plates that report target cell cytotoxicity via electrical impedance (xCelligence, Acea Biosciences,
San Diego, CA, USA) and GUCY2C-directed CAR-T cells rapidly kill GUCY2C-expressing target
cells (minutes), but did not kill cells lacking GUCY2C. In a model of metastatic colorectal cancer,
GUCY2C-directed CAR-T cells reduced the number of tumor nodules and improved survival [36].
Autoimmunity and toxicity were assessed, and there were no apparent signs of tissue damage in
normal tissue. CAR-T cells were engineered to express green fluorescent protein (GFP) and GFP+
CAR-T cells were observed only in the spleen and tumors, with no evidence of CAR-T cells in the small
intestine or colon. Histopathological examination of intestinal tissue showed no signs of pathology
attributed to the CAR-T cell therapy. Thus, the GUCY2C-directed CAR-T cell therapy was proven to
be both effective and safe in mouse models. To date, GUCY2C-directed CAR-T cell therapy has only
been examined in the context of pre-clinical studies. This does not negate the potential for on-target,
off-tumor toxicity in the clinic due to differential expression of GUCY2C between mice and humans.
As human three-dimensional cell culture matrices are becoming more cost-effective, the ability to
examine potential on-target and off-target toxicity prior to direct clinical intervention is increasing
in feasibility. It should also be noted that toxicity does not preclude therapeutic usage. CAR-T cell
therapy against the B-cell marker CD19 regularly causes B-cell aplasia and cytokine storm in patients,
requiring concomitant toxicity management that is both target-specific and outcome-specific [37].
In the context of GUCY2C-directed CAR-T cell therapy, toxicity in the clinical setting can be managed
using RNA delivery of the CAR construct, rather than a viral vector, a dose escalation study design,
suicide switches, and other approaches [34]. Currently, work is underway to characterize a CAR
construct that recognizes human GUCY2C, which can be translated to clinical testing in patients with
advanced gastrointestinal cancers.
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6. Conclusions
Current evidence supports GUCY2C as a safe and effective target for colorectal cancer
immunotherapy. With every study, whether it be for vaccines, immunotoxins, or CAR-T cells,
an extensive portion of the work has been devoted to examining treatment-induced autoimmunity
and toxicity. To date, no treatment modality has demonstrated any signs of serious autoimmunity
either in animal models or in clinical trial patients, supporting the hypothesis that anatomical and
immunological compartmentalization of GUCY2C prevents intestinal targeting by these therapies.
Moreover, both animal models and patient data show that these therapeutics are effective at inducing
anti-cancer responses, and suggest that further clinical development of these therapies could greatly
improve the lives of patients with GUCY2C-expressing cancers, including esophageal, gastric,
pancreatic, and colorectal, establishing GUCY2C-targeted therapies as primary treatment modalities
for these deadly diseases.
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